An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age. Approximately half of the subjects will be recruited during the first study year and will be followed during approximately 6-8 months for efficacy and safety. The recruitment of an independent cohort during the second study year will be based on the results of the first year.